Cargando…
Prevention and management of hyperkalemia in patients treated with renin–angiotensin–aldosterone system inhibitors
Autores principales: | Weinstein, Jordan, Girard, Louis-Philippe, Lepage, Serge, McKelvie, Robert S., Tennankore, Karthik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Joule Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648362/ https://www.ncbi.nlm.nih.gov/pubmed/34872955 http://dx.doi.org/10.1503/cmaj.210831 |
Ejemplares similares
-
Prévention et traitement de l’hyperkaliémie chez les patients sous inhibiteurs du système rénine–angiotensine–aldostérone
por: Weinstein, Jordan, et al.
Publicado: (2022) -
Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia
por: Kohsaka, Shun, et al.
Publicado: (2022) -
Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes
por: An, Jaejin, et al.
Publicado: (2023) -
Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction
por: Rosano, Giuseppe MC, et al.
Publicado: (2019) -
Is It Time to Rethink the Age-Old Practice of Permissive Hyperkalemia in Renin-Angiotensin-Aldosterone Inhibition?
por: Ambruso, Sophia L.
Publicado: (2021)